<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Relapse of <z:e sem="disease" ids="C0277554" disease_type="Disease or Syndrome" abbrv="">primary disease</z:e> and occurrence of new <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancers</z:e> can cause significant morbidity and mortality in recipients of autologous and allogeneic hematopoietic-cell transplantation (HCT) </plain></SENT>
<SENT sid="1" pm="."><plain>Treatment options for relapse are generally limited and can include disease-specific chemotherapy or targeted therapy </plain></SENT>
<SENT sid="2" pm="."><plain>Additional relapse-directed therapies that are available for allogeneic HCT recipients include withdrawal of immunosuppression and donor lymphocyte infusion </plain></SENT>
<SENT sid="3" pm="."><plain>Selected patients can be offered a second transplant procedure </plain></SENT>
<SENT sid="4" pm="."><plain>Newer strategies to eliminate <z:e sem="disease" ids="C0242596" disease_type="Neoplastic Process" abbrv="MRD">minimal residual disease</z:e> and, in allogeneic HCT recipients, to augment the graft-versus-<z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> effect are needed for patients who are at high risk for relapse after HCT </plain></SENT>
<SENT sid="5" pm="."><plain><z:e sem="disease" ids="C0751623" disease_type="Neoplastic Process" abbrv="">Second cancers</z:e> after HCT include post-transplant <z:hpo ids='HP_0005523'>lymphoproliferative disorder</z:hpo>, <z:e sem="disease" ids="C0376545" disease_type="Neoplastic Process" abbrv="">hematologic malignancies</z:e> and new solid <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancers</z:e> </plain></SENT>
<SENT sid="6" pm="."><plain>The incidence of second solid <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancers</z:e> continues to rise without a plateau with increasing follow up of HCT survivors </plain></SENT>
<SENT sid="7" pm="."><plain>Secondary <z:hpo ids='HP_0002863'>myelodysplastic syndrome</z:hpo> and <z:hpo ids='HP_0002488'>acute leukemia</z:hpo> are almost exclusively seen in autologous HCT recipients while post-transplant <z:hpo ids='HP_0005523'>lymphoproliferative disorders</z:hpo> complicate recipients of allogeneic HCT </plain></SENT>
<SENT sid="8" pm="."><plain>Appropriate screening evaluations should be performed in HCT survivors to facilitate early detection and treatment of <z:e sem="disease" ids="C0751623" disease_type="Neoplastic Process" abbrv="">second cancers</z:e> </plain></SENT>
</text></document>